Amarin Corp Plcuk (AMRN) Capital Expenditures (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Capital Expenditures of $2.9 million for Q2 2026, up 7638.46% year-over-year from $37992.0 in Q2 2025, and up 5350.0% quarter-over-quarter from -$56000.0 in Q1 2026.
Amarin Corp Plcuk (AMRN) Capital Expenditures (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Capital Expenditures for 16 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures rose 7638.46% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $2.8 million (up 1944.74% YoY), while the FY2025 annual figure was -$158000.0, down 7.48% from the prior year.
- Capital Expenditures improved to $2.9 million in Q2 2026 per AMRN's latest filing, from -$56000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.9 million in Q2 2026 and bottomed at -$209000.0 in Q3 2023.
- Historically, Capital Expenditures has averaged $204071.4 across 4 years, with a median of -$37000.0 in 2024.
- Annual changes were most pronounced in 2024 — Capital Expenditures slumped 106.47% — and 2026, when it jumped 7638.46%.
- Amarin Corp Plc\Uk's Capital Expenditures stood at -$35000.0 in 2023, then declined by 5.71% to -$37000.0 in 2024, then slumped by 45.95% to -$54000.0 in 2025, then surged by 5544.44% to $2.9 million in 2026.
- Business Quant data shows AMRN's Capital Expenditures at $2.9 million in Q2 2026, -$56000.0 in Q1 2026, and -$54000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 2.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.94 Mn |
| Jun 30, 2026 | 2.94 Mn |
| Mar 31, 2026 | -56,000.00 |
| Mar 31, 2026 | -56,000.00 |
| Dec 31, 2025 | -54,000.00 |
| Dec 31, 2025 | -54,000.00 |
| Sep 30, 2025 | -26,000.00 |
| Sep 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -39,000.00 |
| Jun 30, 2025 | -39,000.00 |
| Mar 31, 2025 | -39,000.00 |
| Mar 31, 2025 | -39,000.00 |
| Dec 31, 2024 | -37,000.00 |
| Dec 31, 2024 | -37,000.00 |
| Sep 30, 2024 | -37,000.00 |
| Sep 30, 2024 | -37,000.00 |
| Jun 30, 2024 | -37,000.00 |
| Jun 30, 2024 | -37,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Mar 31, 2024 | -36,000.00 |